Personalis Free Cash Flow 2018-2023 | PSNL

Personalis free cash flow from 2018 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Personalis Annual Free Cash Flow
2023 -67.17
2022 -120.13
2021 -81.91
2020 -45.90
2019 -26.45
2018 -2.28
2017 -4.87
Personalis Quarterly Free Cash Flow
2023-12-31 -67.17
2023-09-30 -50.23
2023-06-30 -32.68
2023-03-31 -19.52
2022-12-31 -120.13
2022-09-30 -93.83
2022-06-30 -57.65
2022-03-31 -19.99
2021-12-31 -81.91
2021-09-30 -63.06
2021-06-30 -42.22
2021-03-31 -12.18
2020-12-31 -45.90
2020-09-30 -42.53
2020-06-30 -24.85
2020-03-31 -8.72
2019-12-31 -26.45
2019-09-30 -26.94
2019-06-30 -13.64
2019-03-31 -0.89
2018-12-31
2018-09-30 -4.81
2018-06-30 -2.44
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.066B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.585B 5.27
Dr Reddy's Laboratories (RDY) India $11.835B 18.71
Aspen Pharmacare (APNHY) South Africa $4.900B 0.00
BridgeBio Pharma (BBIO) United States $4.401B 0.00
Bausch Health Cos (BHC) Canada $3.128B 2.44
Amphastar Pharmaceuticals (AMPH) United States $2.004B 13.71
Supernus Pharmaceuticals (SUPN) United States $1.656B 0.00
Taysha Gene Therapies (TSHA) United States $0.439B 0.00
Generation Bio (GBIO) United States $0.199B 0.00
Assembly Biosciences (ASMB) United States $0.074B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.026B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00